Drug Information

Drug General Information
Drug ID
D02ONR
Former ID
DNCL002629
Drug Name
RG7686
Drug Type
Antibody
Indication Hepatocellular carcinoma [ICD9: 155; ICD10:C22.0] Phase 2 [523754], [543113]
Company
Roche
Target and Pathway
Target(s) Glypican-3 Target Info [532207]
KEGG Pathway Proteoglycans in cancer
NetPath Pathway IL2 Signaling Pathway
Pathway Interaction Database Glypican pathway
Glypican 3 network
Reactome A tetrasaccharide linker sequence is required for GAG synthesis
HS-GAG degradation
Retinoid metabolism and transport
WikiPathways Visual phototransduction
References
Ref 523754ClinicalTrials.gov (NCT01507168) A Study of RO5137382 (GC33) in Patients With Advanced or Metastatic Hepatocellular Carcinoma. U.S. National Institutes of Health.
Ref 543113(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8406).
Ref 532207First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15;19(4):920-8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.